Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chemed Corp (NY:CHE)

597.74 -21.47 (-3.47%)
Streaming Delayed Price Updated: 2:40 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Chemed Corp

< Previous 1 2 3 Next >
Chemed (CHE): Buy, Sell, or Hold Post Q4 Earnings?
Chemed currently trades at $601.30 per share and has shown little upside over the past six months, posting a middling return of 2.7%. However, the stock is beating the S&P 500’s 3.3% decline during... 
Via StockStory
Topics Stocks
Exposures US Equities
Q4 Earnings Roundup: Brookdale (NYSE:BKD) And The Rest Of The Senior Health, Home Health & Hospice Segment
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the senior health, home health & hospice industry, including Brookdale (NYSE:BKD) and its peers. 
Via StockStory
Topics Economy Retirement
Exposures Interest Rates Pension
Here's How Much $1000 Invested In Chemed 20 Years Ago Would Be Worth Today
Via Benzinga
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
$1000 Invested In Chemed 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Senior Health, Home Health & Hospice Stocks Q4 Teardown: AdaptHealth (NASDAQ:AHCO) Vs The Rest
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the senior health, home health & hospice industry, including AdaptHealth (NASDAQ:AHCO)... 
Via StockStory
Topics Economy
Exposures Interest Rates
Chemed’s (NYSE:CHE) Q4: Beats On Revenue
Healthcare services company Chemed Corporation (NYSE:CHE) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 9.2% year on year to $640 million. Its non-GAAP profit of $6.83 per share... 
Via StockStory
Topics Economy
Exposures Interest Rates
What To Expect From Chemed’s (CHE) Q4 Earnings
Healthcare services company Chemed Corporation (NYSE:CHE) will be reporting results tomorrow after market hours. Here’s what to expect. 
Via StockStory
Winners And Losers Of Q3: AdaptHealth (NASDAQ:AHCO) Vs The Rest Of The Senior Health, Home Health & Hospice Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how AdaptHealth (NASDAQ:AHCO) and... 
Via StockStory
Topics Economy
Exposures Interest Rates
$100 Invested In Chemed 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much $1000 Invested In Chemed 20 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much You Would Have Made Owning Chemed Stock In The Last 20 Years
Via Benzinga
Senior Health, Home Health & Hospice Stocks Q3 Results: Benchmarking Brookdale (NYSE:BKD)
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Brookdale (NYSE:BKD) and its peers. 
Via StockStory
Topics Economy
Exposures Interest Rates
Q3 Earnings Highs And Lows: Chemed (NYSE:CHE) Vs The Rest Of The Senior Health, Home Health & Hospice Stocks
Looking back on senior health, home health & hospice stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Chemed (NYSE:CHE) and its peers. 
Via StockStory
Topics Economy
Exposures Interest Rates
Senior Health, Home Health & Hospice Stocks Q3 Teardown: The Pennant Group (NASDAQ:PNTG) Vs The Rest
Let’s dig into the relative performance of The Pennant Group (NASDAQ:PNTG) and its peers as we unravel the now-completed Q3 senior health, home health & hospice earnings season. 
Via StockStory
Topics Economy
Exposures Interest Rates
Senior Health, Home Health & Hospice Stocks Q3 Earnings Review: Option Care Health (NASDAQ:OPCH) Shines
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Option Care Health (NASDAQ:OPCH) and its peers. 
Via StockStory
Topics Economy
Exposures Interest Rates
(CHE) - Analyzing Chemed's Short Interest
Via Benzinga
$100 Invested In Chemed 10 Years Ago Would Be Worth This Much Today
Via Benzinga
How Is The Market Feeling About Chemed?
Via Benzinga
Senior Health, Home Health & Hospice Stocks Q3 Teardown: BrightSpring Health Services (NASDAQ:BTSG) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at senior health, home health & hospice... 
Via StockStory
Topics Economy
Exposures Interest Rates
Q3 Earnings Highlights: Addus HomeCare (NASDAQ:ADUS) Vs The Rest Of The Senior Health, Home Health & Hospice Stocks
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the senior health, home health & hospice industry, including Addus HomeCare... 
Via StockStory
Topics Economy
Exposures Interest Rates
Peering Into Chemed's Recent Short Interest
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $13,000 Today
Via Benzinga
Here's How Much You Would Have Made Owning Chemed Stock In The Last 20 Years
Via Benzinga
Looking Into Chemed's Recent Short Interest
Via Benzinga
Exxon Mobil, Chemed, Las Vegas Sands And More On CNBC's 'Final Trades'
Joshua Brown of Ritholtz Wealth Management picked an oil ETF as a hedge against Iran, while Jim Lebenthal of Cerity Partners picked Exxon. 
Via Benzinga
Topics ETFs
3 Ways to Play the Long-Term Care Crisis in 2024
As America’s population ages, long-term care stocks will become more attractive to investors. Here are three that already are. 
Via InvestorPlace
CHE Stock Earnings: Chemed Misses EPS, Misses Revenue for Q2 2024
CHE stock results show that Chemed missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.